A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT01733758 on ClinicalTrials.gov · last registry update 2016-09-22

Finished June 2014, after enrolling 494 people. Primary outcome, as filed: Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: GlaxoSmithKline
Sponsor type: Industry
Enrollment: 494
Started: 2013-02
Primary completion: 2014-06 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.